Explore Eli Lilly's recent clinical data on retatrutide, Foundayo, and eloraTZP. We translate the emerging science behind multi-pathway medications.
On September 15, 2026, Eli Lilly announced new cardiometabolic-health data. The pharmaceutical company stated it will present these findings at the European Association for the Study of Diabetes 62nd annual meeting. This major scientific gathering is scheduled to take place in Milan from September 28 to October 2. The scheduled presentations highlight a notable shift in weight science research.
The medical community is actively moving from single-pathway medicines toward multi-receptor agents and combination approaches. The headline dataset for this upcoming presentation is the Phase 3 TRIUMPH-2 study. This clinical trial investigated retatrutide in adults with obesity or overweight and type 2 diabetes. This specific population is important when interpreting the broader significance of the results.
Beyond the injectable retatrutide data, Lilly also plans to present Phase 3 results for an oral medication. This drug is known by the brand name Foundayo. Additionally, the company will share Phase 1 data for an investigational combination therapy named eloraTZP. These three distinct developments illustrate the expanding landscape of medical weight management.
These investigational treatments target completely different biological mechanisms within the human body. Retatrutide operates as an investigational once-weekly triple agonist. It specifically activates the GIP, GLP-1, and glucagon receptors. Existing treatments like tirzepatide already combine GIP and GLP-1 activity to help regulate metabolism.
Retatrutide is uniquely designed to add glucagon-receptor activity to those two established incretin pathways. Lilly is also exploring new delivery methods with its ACHIEVE program. The company describes Foundayo as a once-daily, non-peptide oral GLP-1 receptor agonist. This oral formulation can reportedly be taken without restrictions on food or water intake.
Because it is a pill, Foundayo is positioned as a potential alternative to injectable metabolic medicines. The third major focus of the announcement is combination therapy. EloraTZP is an investigational treatment combining eloralintide and tirzepatide. Eloralintide functions as an investigational once-weekly selective amylin-receptor agonist.
By combining eloralintide with tirzepatide, researchers aim to influence multiple distinct metabolic signals simultaneously. For years, I watched smart, capable people blame themselves when standard diet advice failed them. They would cut calories drastically, run themselves into the ground and inevitably regain the weight. I realized we were treating a complex biological and psychological system like a simple math problem. These new multi-pathway treatments reflect how we must focus on comprehensive metabolic health rather than simple restriction.
Financial markets often react aggressively to pharmaceutical press releases. A recent market-focused report indicated that Berenberg upgraded Lilly to a "Buy" rating. The analysts cited expectations that the company could exceed its 2026 financial projections. They also noted the company could continue benefiting from its strong position in obesity medicines.
However, enthusiastic investment outlooks do not equal clinical certainty for everyday patients. The mainstream media frequently highlights the largest weight reduction percentages without providing proper medical context. It is essential to remember that retatrutide remains strictly an investigational medication. The TRIUMPH-2 trial specifically enrolled adults with obesity or overweight and type 2 diabetes.
These specific trial outcomes cannot automatically be generalized to adults without diabetes. The results also may not apply to individuals with lower baseline body weights. Furthermore, the cardiovascular data for Foundayo requires careful interpretation rather than absolute certainty. The reported cardiovascular numbers arrived with wide confidence intervals that cross the neutral hazard-ratio value of 1.0.
Long-term metabolic maintenance remains a massive challenge that new medications alone cannot completely solve. A report summarizing the STEP 1 extension study revealed what happens after treatment stops. Participants regained an average of 11.6 percentage points of body weight during the year after semaglutide withdrawal. This specific regain represented roughly two-thirds of their previous weight loss.
Comparing early data across different pharmaceutical trials also creates significant confusion. Novo Nordisk previously reported that its investigational CagriSema combination produced 15.7% weight loss at 68 weeks. This investigation of combination treatments involved a completely separate study and patient population. It should never be treated as a direct comparison with the TRIUMPH-2 retatrutide results.
The recently announced trials offer specific numerical outcomes for these emerging investigational treatments. In the Phase 3 TRIUMPH-2 study, Lilly reported significant outcomes at the 80-week mark. Participants receiving retatrutide lost up to an average of 49.6 pounds. This measurement translates to 22.5 kilograms and 20.8% of their body weight.
This same clinical analysis reported an average A1C reduction of up to 1.6 percentage points. The company stated that these specific figures use an efficacy estimand framework. This statistical method estimates outcomes as though randomized participants had remained on their study treatment. It is important to note that the public announcement did not provide the full dataset.
The ACHIEVE-4 trial compared Foundayo with insulin glargine in adults with type 2 diabetes. These participants also had obesity or overweight and faced an increased cardiovascular risk. Foundayo met the study non-inferiority criterion and showed a reported 16% lower risk of MACE-4 events. The 95.0% confidence interval for this outcome ranged from 0.59 to 1.20.
For MACE-3 events, Lilly reported a 23% lower risk during the ACHIEVE-4 trial. The hazard ratio was 0.77, and the 95.0% confidence interval landed between 0.52 and 1.13. These specific intervals explain why the findings merely suggest potential cardiometabolic care benefits. They do not provide definitive clinical proof of cardiovascular prevention.
The Phase 1 data for eloraTZP showed very early results over a 16-week period. Eloralintide 3 milligrams added to tirzepatide 5 milligrams produced 17% weight loss. This result was compared with a 10% reduction for tirzepatide 5 milligrams alone. Because this is merely a Phase 1 result, it should be viewed strictly as a development-stage signal.
Future scientific research must clarify several critical questions before these options become widely accessible. We need detailed data concerning gastrointestinal adverse events, serious adverse events, and changes in lean mass. Currently, the available announcements do not establish how much weight regain would occur after stopping retatrutide.
Kenneth Custer, Lilly’s executive vice president and president of Cardiometabolic Health, offered a helpful perspective. He stated that more than a billion people worldwide are living with diabetes or obesity. Custer argued that their highly diverse needs require multiple treatment options based on different mechanisms. The next generation of medicines may finally offer these varied routes of administration.
Clinical obesity care is commonly framed around several complementary pillars of health. As discussed by the Obesity Medicine Association, these include healthful nutrition, routine physical activity, and behavior modification. The framework also includes indicated obesity medications and, for appropriate patients, bariatric procedures. Medication development does not eliminate the need for quality nutrition or ongoing clinical follow-up.
Our team emphasizes that focusing solely on medical interventions ignores the broader ecosystem of human health. Recovery, stress management, and sleep remain critical components of any sustainable physical transformation. A medication can alter your biological signals, but it cannot organize your evening routine or manage your daily stress. True metabolic resilience requires building supportive habits around whatever clinical tools you choose to utilize.
Nutrition goals can remain deliberately ordinary and sustainable while navigating these new pharmaceutical treatments. Patients should consistently focus on adequate protein, sufficient fiber, and regular meals that reduce extreme hunger. A long-term health plan requires a flexible pattern of eating. This routine must be maintained easily during work, travel, and busy family life.
WeightRestart shares research-led guidance on weight loss, metabolism, nutrition, strength, appetite, sleep and recovery. Our goal is to make complex health information clear, practical and useful for people building progress they can maintain.
Learn how to build a weight-management approach around better information, realistic expectations and habits you can keep using.
read the blog
